Induction of Tolerogenic Dendritic Cells by NF-κB Blockade and Fcγ Receptor Modulation

  • Leandro J. Carreño
  • Claudia A. Riedel
  • Alexis M. Kalergis
Part of the Methods in Molecular Biology book series (MIMB, volume 677)


Autoimmune diseases develop as a result of an unbalanced adaptive immunity that targets self-antigens and causes destruction of healthy host tissues. Maintenance of peripheral immune tolerance to self- antigens is mainly mediated by dendritic cells (DCs), professional antigen-presenting cells that modulate the activation of T cells. Due to their key role as regulators of adaptive immunity, identification of means of enhancing DC tolerogenic capacity and therapeutic potential is a priority goal to reduce autoimmune disease burden in an antigen-specific manner. Our findings suggest novel approaches to enhance DC capacity to induce self-tolerance and reduce the severity of autoimmune disorders. Specifically, we have shown, both in vitro and in vivo, that NF-κB blockade on DCs by andrographolide or rosiglitazone can significantly enhance the tolerogenic capacity of DCs. Furthermore, we have observed that expression ratio of the activating FcγRIII or the inhibitory FcγRIIb is determinant for the tolerogenic potential of DCs. In this chapter, we describe the procedures to produce tolerogenic DCs and explain the potential therapeutic use of two NF-κB inhibitors for the treatment of autoimmune disease models, such as experimental autoimmune encephalomyelitis (EAE) and systemic lupus erythematosus (SLE) in mice. Therefore, our studies support the notion that FcγRs and NF-κB can be considered as pharmacological targets to increase the capacity of DCs to induce or restore self-tolerance and decrease inflammatory damage to self-tissues.

Key words

Dendritic cells NF-κB Andrographolide Rosiglitazone Fcγ receptors EAE SLE 



Authors would like to thank all the trainees who contributed to the articles from our group cited in this publication. This work was supported by Grants FONDECYT 1070352 and 1085281 and Millennium Nucleus on Immunology and Immunotherapy (P07/088-F)


  1. 1.
    Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y. J., Pulendran, B., and Palucka, K. (2000) Immunobiology of dendritic cells, Annu Rev Immunol 18, 767–811.PubMedCrossRefGoogle Scholar
  2. 2.
    Iruretagoyena, M. I., Wiesendanger, M., and Kalergis, A. M. (2006) The dendritic cell-T cell synapse as a determinant of autoimmune pathogenesis, Curr Pharm Des 12, 131–147.PubMedCrossRefGoogle Scholar
  3. 3.
    Iruretagoyena, M. I., Lezana, J. P. and Kalergis, A. M. (2005) Interactions at the Dendritic Cell/ T-Cell Interface Define the Balance between Immunity and Tolerance. Transfus Med Hemother, 32:373–383.PubMedCrossRefGoogle Scholar
  4. 4.
    Ouaaz, F., Arron, J., Zheng, Y., Choi, Y., and Beg, A. A. (2002) Dendritic cell development and survival require distinct NF-kappaB subunits, Immunity 16, 257–270.PubMedCrossRefGoogle Scholar
  5. 5.
    Zanetti, M., Castiglioni, P., Schoenberger, S., and Gerloni, M. (2003) The role of relB in regulating the adaptive immune response, Ann N Y Acad Sci 987, 249–257.PubMedCrossRefGoogle Scholar
  6. 6.
    Saccani, S., Pantano, S., and Natoli, G. (2003) Modulation of NF-kappaB activity by exchange of dimers, Mol Cell 11, 1563–1574.PubMedCrossRefGoogle Scholar
  7. 7.
    Iruretagoyena, M. I., Sepulveda, S. E., Lezana, J. P., Hermoso, M., Bronfman, M., Gutierrez, M. A., Jacobelli, S. H., and Kalergis, A. M. (2006) Inhibition of nuclear factor-kappa B enhances the capacity of immature dendritic cells to induce antigen-specific tolerance in experimental autoimmune encephalomyelitis, J Pharmacol Exp Ther 318, 59–67.PubMedCrossRefGoogle Scholar
  8. 8.
    Kalergis, A. M., Iruretagoyena, M. I., Barrientos, M. J., González, P. A., Herrada, A. A., Leiva, E. D., Gutiérrez, M. A., Riedel, C. A., Bueno, S. A., and Jacobelli, S. H. (2009) Modulation of nuclear factor-κB activity can influence the susceptibility to systemic lupus erythematosus. Immunology 128, e306–e314.PubMedCrossRefGoogle Scholar
  9. 9.
    Iruretagoyena, M. I., Tobar, J. A., Gonzalez, P. A., Sepulveda, S. E., Figueroa, C. A., Burgos, R. A., Hancke, J. L., and Kalergis, A. M. (2005) Andrographolide interferes with T cell activation and reduces experimental autoimmune encephalomyelitis in the mouse, J Pharmacol Exp Ther 312, 366–372.PubMedCrossRefGoogle Scholar
  10. 10.
    Kelly, D., Campbell, J. I., King, T. P., Grant, G., Jansson, E. A., Coutts, A. G., Pettersson, S., and Conway, S. (2004) Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA, Nat Immunol 5, 104–112.PubMedCrossRefGoogle Scholar
  11. 11.
    Nimmerjahn, F., and Ravetch, J. V. (2007) Fc-receptors as regulators of immunity, Adv Immunol 96, 179–204.PubMedCrossRefGoogle Scholar
  12. 12.
    Ravetch, J. V., and Bolland, S. (2001) Igg fc receptors, Annu Rev Immunol 19, 275–290.PubMedCrossRefGoogle Scholar
  13. 13.
    Nimmerjahn, F., Bruhns, P., Horiuchi, K., and Ravetch, J. V. (2005) FcgammaRIV: a novel FcR with distinct IgG subclass specificity, Immunity 23, 41–51.PubMedCrossRefGoogle Scholar
  14. 14.
    Kalergis, A. M. (2003) Modulation of T cell immunity by TCR/pMHC dwell time and activating/inhibitory receptor pairs on the antigen-presenting cell, Curr Pharm Des 9, 233–244.PubMedCrossRefGoogle Scholar
  15. 15.
    Kalergis, A. M., and Ravetch, J. V. (2002) Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells, J Exp Med 195, 1653–1659.PubMedCrossRefGoogle Scholar
  16. 15.
    Iruretagoyena, M. I., Riedel, C. A., Leiva, E. D., Gutierrez, M. A., Jacobelli, S. H., and Kalergis, A. M. (2008) Activating and inhibitory Fcgamma receptors can differentially modulate T cell-mediated autoimmunity, Eur J Immunol 38, 2241–2250.PubMedCrossRefGoogle Scholar
  17. 17.
    Bolland, S., and Ravetch, J. V. (2000) Spon taneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis, Immunity 13, 277–285.PubMedCrossRefGoogle Scholar
  18. 18.
    Clynes, R., Dumitru, C., and Ravetch, J. V. (1998) Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis, Science 279, 1052–1054.PubMedCrossRefGoogle Scholar
  19. 19.
    Carreño L.J., Pacheco, R., Gutierrez, M. A., Jacobelli, S., and Kalergis, A. M. (2009) Disease activity in systemic lupus erythematosus is associated with an altered expression of low-affinity-FcγRs and costimulatory molecules on dendritic cells. Immunology 128, 334–341.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press 2010

Authors and Affiliations

  • Leandro J. Carreño
    • 1
  • Claudia A. Riedel
    • 2
  • Alexis M. Kalergis
    • 3
  1. 1.Millenium Nucleus of Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias BiológicasPontificia Universidad Catolica de ChileSantiagoChile
  2. 2.Millenium Nucleus of Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Laboratorio de Biología Celular y Farmacología, Departamento de Ciencias Biológicas, Facultad de Ciencias BiológicasPontificia Universidad Catolica de ChileSantiagoChile
  3. 3.Millenium Nucleus of Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Departamento de Reumatología, Facultad de MedicinaPontificia Universidad Catolica de ChileSantiagoChile

Personalised recommendations